| Market Cap | 491.02M | P/E | - | EPS this Y | -8.70% | Ern Qtrly Grth | - |
| Income | -92.59M | Forward P/E | -6.78 | EPS next Y | 28.50% | 50D Avg Chg | 11.00% |
| Sales | - | PEG | -0.15 | EPS past 5Y | - | 200D Avg Chg | 129.00% |
| Dividend | N/A | Price/Book | 2.71 | EPS next 5Y | 32.40% | 52W High Chg | -2.00% |
| Recommedations | 3.00 | Quick Ratio | 16.79 | Shares Outstanding | 36.95M | 52W Low Chg | 474.00% |
| Insider Own | 1.13% | ROA | -22.28% | Shares Float | 19.35M | Beta | -0.56 |
| Inst Own | 104.91% | ROE | -42.37% | Shares Shorted/Prior | 867.97K/2.26M | Price | 13.29 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 703,041 | Target Price | 8.50 |
| Oper. Margin | - | Earnings Date | Mar 27 | Volume | 1,790,496 | Change | 0.00% |
Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.
| Piper Sandler | Neutral | Oct 19, 22 |
| William Blair | Market Perform | Oct 19, 22 |
| HC Wainwright & Co. | Neutral | Oct 18, 22 |
| William Blair | Outperform | Sep 29, 22 |
| Piper Sandler | Overweight | May 18, 22 |
| HC Wainwright & Co. | Buy | Apr 27, 21 |
| B of A Securities | Neutral | Mar 30, 21 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| PARMAR KUSH | Director Director | Dec 31 | Sell | 18 | 470,000 | 8,460,000 | 982,453 | 12/31/20 |